New scan could spot deadliest prostate cancers
NCT ID NCT05245006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to see if this scan can better detect hard-to-find tumors, which could help doctors choose the right treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 89Zr-DFO-YS5 (a radioactive imaging agent) and YS5 antibody
- What this could lead to
- If successful, this imaging method could help doctors identify aggressive prostate cancers that are hard to spot with current scans, potentially guiding more effective treatments.
- What could go wrong
- This is a very early, small study (30 men) focused on testing the imaging agent's safety and effectiveness. It may not lead to a widely used test, and the results may not apply to all prostate cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A surgical tweak may speed bladder control recovery after prostate removal
- Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Blood DNA fragments and MRI join forces to spot hidden prostate cancer
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can an AI agent match expert urologists? a major test begins